OverviewSuggest Edit

DiaSorin is a company that produces and markets in vitro diagnostics reagent kits used in immunodiagnostics and molecular diagnostics. Its line of products used by diagnostic laboratories that are part of hospital facilities or operate independently can meet the needs of the following clinical areas: infectious diseases, cardiac markers, bone metabolism, hepatitis and retrovirus, oncology, and endocrinology. DiaSorin also provides life science products that have a range of applications including academic and scientific research, public health and food safety, plant pathogens detection and cell counts, viability, and cell health analyses.
TypePublic
Founded1968
HQSaluggia, IT
Websitediasoringroup.com
Employee Ratings3.7

Latest Updates

Employees (est.) (Jun 2021)2,104(+2%)
Job Openings46
Revenue (FY, 2020)€881.3 M(+25%)
Share Price (May 2022)€119.1(+7%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at DiaSorin

Carlo Rosa

Carlo Rosa

Chief Executive Officer
Gustavo Denegri

Gustavo Denegri

Chairman
Piergiorgio Pedron

Piergiorgio Pedron

Chief Financial Officer
Stefano Ronchi

Stefano Ronchi

Senior Corporate VP Human Resources
Ugo Gay

Ugo Gay

Senior Corporate Vice President Industrial Operations
Chen Even

Chen Even

Chief Commercial Officer
Show more

DiaSorin Office Locations

DiaSorin has offices in Saluggia, Italy, Cypress, Stillwater and in 20 other locations
Saluggia, IT (HQ)
Via Crescentino, snc
Italy, IT
Via Roberto Lepetit, 34
Saluggia, IT
via crescentino snc 13040
Macquarie Park, AU
11 Talavera Road
Wien, AT
Schottenring 16/Top 08-10A
Anderlecht, BE
Paapsemlaan & Boulevard Paepsem
Show all (25)

DiaSorin Financials and Metrics

DiaSorin Revenue

DiaSorin's revenue was reported to be €881.31 m in FY, 2020
EUR

Revenue (Q3, 2021)

343.5m

Gross profit (Q3, 2021)

195.1m

Net income (Q3, 2021)

79.3m

EBITDA (Q3, 2021)

80.4m

EBIT (Q3, 2021)

109.9m

Market capitalization (13-May-2022)

6.5b

Closing stock price (13-May-2022)

119.1

EV

6.5b
DiaSorin's current market capitalization is €6.5 b.
Annual
EURFY, 2018FY, 2019FY, 2020

Revenue

669.2m706.3m881.3m

Cost of goods sold

(162.6m)(134.1m)(219.6m)

Gross profit

507.9m572.2m661.7m

R&D expense

(45.1m)(47.9m)(50.8m)
Quarterly
EURQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Revenue

170.8m179.5m174.8m174.6m207.7m227.8m266.7m248.7m343.5m

Cost of goods sold

(52.2m)(25.7m)(84.1m)(54.0m)(31.3m)(105.1m)(81.6m)(49.0m)(148.4m)

Gross profit

118.6m153.7m90.8m120.6m176.4m122.7m185.1m199.7m195.1m

R&D expense

(11.7m)(11.6m)(11.1m)(12.4m)(13.1m)(12.5m)(23.5m)(20.8m)
Annual
EURFY, 2018FY, 2019FY, 2020

Cash

73.1m157.6m339.9m

Accounts Receivable

131.1m132.5m165.7m

Inventories

160.4m171.1m191.2m
Quarterly
EURQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Cash

90.1m138.7m896.8m

Accounts Receivable

136.3m158.2m158.4m

Inventories

167.5m195.3m203.0m
Annual
EURFY, 2018FY, 2019FY, 2020

Net Income

158.1m175.7m248.3m

Depreciation and Amortization

50.8m59.0m58.8m

Inventories

(14.4m)(9.8m)(30.2m)

Accounts Payable

(8.6m)(1.8m)11.0m
Quarterly
EURQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Net Income

84.0m94.7m157.6m150.0m339.9m

Depreciation and Amortization

29.2m30.0m29.5m

Inventories

(7.3m)(29.4m)(20.0m)

Accounts Payable

(5.3m)6.5m13.4m
EURFY, 2018

Revenue/Employee

339.5k
Show all financial metrics

DiaSorin Operating Metrics

FY, 2018Q2, 2019FY, 2019FY, 2020

Countries

24

Distributors

200200

Manufacturing Facilities

766

Manufacturing Sites

12145
Show all operating metrics

DiaSorin Acquisitions / Subsidiaries

Company NameDateDeal Size
LuminexApril 11, 2021$1.8 b

DiaSorin Revenue Breakdown

Embed Graph

DiaSorin revenue breakdown by business segment: 100.0% from HEALTH CARE DIVERSIFIED

Human Capital Metrics

DiaSorin's employees are reported to be approximately 45% female and 55% male.
Embed Graph
Show all human capital metrics

DiaSorin Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

DiaSorin Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

DiaSorin Online and Social Media Presence

Embed Graph

DiaSorin News and Updates

Global Lyme Alliance and DiaSorin Announce Partnership Seeking Study Volunteers to Advance an Innovative Lyme Disease Diagnostic

Today, Global Lyme Alliance (GLA) and DiaSorin, a global leader in the laboratory diagnostics market specializing in the immunodiagnostics and molecular diagnostics segments, announce a partnership to raise awareness of DiaSorin’s LIAISON LymeDetect® study.

DiaSorin Q2 Revenues Rise 20 Percent on SARS-CoV-2 Testing Demand

DiaSorin said on Friday that its second quarter revenues rose 20 percent year over year, driven by strength in molecular diagnostic test sales.

Join the special DiaSorin’s Integrated Session during the 31st ECCMID

DiaSorin’s Integrated Session during the 31st ECCMID, the European Congress of ESCMID - European Society of Clinical Microbiology and Infectious Diseases, on “Diagnosis and immune response of SARS-CoV-2-infection” with the participation of international experts.

DiaSorin announces completion of the acquisition of Luminex Corporation

DiaSorin S.p.A. (“DiaSorin”; FTSE MIB: DIA) announces it has completed the acquisition of Luminex Corporation (“Luminex”; NASDAQ: LMNX) for a price of USD 37.00 per share that corresponds to a total equity value of approximately USD 1.8 billion.

Today we report our Q1 2021 results

Today we report our Q1 2021 results - Significant growth in Revenues and Profitability, Strong Operating Cash Flow Generation and Record Net Financial Position

DiaSorin to acquire Luminex Corporation for USD 37.00 per share or approximately USD 1.8 billion

DiaSorin S.p.A. ("DiaSorin"; FTSE MIB: DIA) today announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex Corporation ("Luminex";NASDAQ: LMNX) for a price of USD 37.00 per share in an all-cash transaction. This correspon…
Show more

DiaSorin Blogs

DiaSorin and B·R·A·H·M·S, part of Thermo Fisher Scientific, partner to develop and commercialize the new LIAISON® B·R·A·H·M·S MR-proADM™

Mon, 05/09/2022 - 07:02 pdfDownload press release173.49KB Add to print basket Go to print basket Add to bookmarks Add note Go to note basket Send to friend Italiano

Strong growth in revenues and cash flow generation in Q1 2022

Saluggia (Italy), May 6, 2022 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the research, production and marketing of diagnostic tests and internationally active in the Life Science sector, meeting today examined and approv…

Strong growth in revenues and cash flow generation in Q1 2022 - Full Year 2022 Guidance revised upwards

Fri, 05/06/2022 - 16:45 pdfDownload press release304.04KB Add to print basket Go to print basket Add to bookmarks Add note Go to note basket Send to friend Italiano

Report on the remuneration policy for the year 2022 and remuneration paid in the year 2021

Language English Thu, 04/07/2022 - 18:10 Allegati:  pdfDownload file924.14KB Add to print basket Go to print basket Add to bookmarks Add note Go to note basket Send to friend Italiano

New proposal for resolution related to the remuneration of the Board of Statutory Auditors

Fri, 04/22/2022 - 12:37 pdfDownload file281.82KB Add to print basket Go to print basket Add to bookmarks Add note Go to note basket Send to friend Italiano

DiaSorin: Publication of the updated proxy forms for voting through the Designated Representative

Wed, 04/13/2022 - 16:43 pdfDownload file282.86KB Add to print basket Go to print basket Add to bookmarks Add note Go to note basket Send to friend Italiano
Show more

DiaSorin Frequently Asked Questions

  • When was DiaSorin founded?

    DiaSorin was founded in 1968.

  • Who are DiaSorin key executives?

    DiaSorin's key executives are Carlo Rosa, Gustavo Denegri and Piergiorgio Pedron.

  • How many employees does DiaSorin have?

    DiaSorin has 2,104 employees.

  • What is DiaSorin revenue?

    Latest DiaSorin annual revenue is €881.3 m.

  • What is DiaSorin revenue per employee?

    Latest DiaSorin revenue per employee is €418.9 k.

  • Who are DiaSorin competitors?

    Competitors of DiaSorin include OpGen, Akonni Biosystems and Cisbio.

  • Where is DiaSorin headquarters?

    DiaSorin headquarters is located at Via Crescentino, snc, Saluggia.

  • Where are DiaSorin offices?

    DiaSorin has offices in Saluggia, Italy, Cypress, Stillwater and in 20 other locations.

  • How many offices does DiaSorin have?

    DiaSorin has 25 offices.